2011-06-06 - 乳癌リスクが高い閉経後女性が参加したプラセボ対照大規模試験（NCIC CTG MAP.3試験）の僅か3年の追跡調査でアロマターゼ阻害剤エキセメスタン（exemestane）の有意な浸潤性乳癌抑制効果が示されました。
Aromasin cuts risk of breast cancer in some groups
* Cuts breast cancer risk 65 pct in high-risk population
* Pfizer drug now available as generic, cost has dropped
By Debra Sherman
CHICAGO, June 4 (Reuters) - Pfizer Inc's (PFE.N) breast cancer drug Aromasin, now available in a generic version, reduced the risk of developing the cancer by 65 percent in post-menopausal women, researchers said on Saturday.
A late-stage trial of 4,560 post-menopausal women who were at increased risk of developing breast cancer found that those who took the drug, also known as exemestane, had fewer invasive breast cancers after 3 years and without severe side effects.
"We are delighted with this two-thirds reduction," Dr. Paul Goss, director of Breast Cancer Research at Massachusetts General Hospital, said in a telephone interview.
He noted that there were fewer of the more aggressive types of tumors in patients who took the drug, but the limitation of the study was that the median follow-up was just 3 years.
The results were presented in Chicago at the annual meeting of the American Society of Clinical Oncology.
An estimated 1.3 million women are diagnosed with breast cancer worldwide each year and nearly 500,000 die of the disease.
The study broke participants up into two groups: One got the drug and the other got a placebo. There were 11 invasive breast cancers reported in the drug group compared with 32 in the placebo group. There were also fewer cases of precursor lesions in the group that got exemestane.
Goss, who led the study, noted that tamoxifen has been used for years to prevent breast cancer, but had serious side effects, including raising the risk of developing uterine cancer, cataract formations and stroke.
MILDER SIDE EFFECTS
Exemestane did not cause high levels of toxicity, he said. Its side effects were much milder that those seen with tamoxifen, he said, although there was a slight increase in osteopenia -- low bone density, but not low enough to be classified as osteoporosis.
Other side effects reported in the study included hot flashes, sweating, fatigue, and insomnia.
"Age is the single biggest risk factor for developing breast cancer. Once you are 60, your risk increases so this (research) merits consideration for prevention. What we don't know is whether patients need to take this pill for life."
After 5 years, there was no dangerous accumulation of toxicity from the drug, he said.
"I can't look someone in the eye and swear it won't be (toxic over a longer period of time), but there's large evidence that the drug is safe," Goss said.
People have been taking statins to lower cholesterol and antihypertensive medications to reduce blood pressure for years, Goss noted. "This is the same concept."
And the price of exemestane has fallen significantly.
The drug, which lost its patent protection on April 1, 2011, generated sales of $483 million for Pfizer in 2010.
Commercially, even with its patent still protected, Aromasin was only a moderate seller in first quarter, with sales down 11 pct to $114 million.
The once-a-day oral tablet was originally approved to treat advanced breast cancer in post-menopausal women who had already been treated with tamoxifen for 2 to 3 years. The drug is also used to treat women whose breast cancer worsened while they were taking tamoxifen.
The drug is a hormone therapy classified as an "aromatase inhibitor," which work by decreasing the amount of estrogen the body produces. Lower estrogen levels can slow or even stop the growth of some breast tumors that need estrogen to grow.
(Reporting by Debra Sherman, Editing by Sandra Maler)
« | HOME | »
Welcome to FC2!
- Lemongrass may be effective to kill Zika virus lavaes (07/30)
- Second Skin (07/25)
- Summer Skin Care Tips (08/05)
- Skin & Excercise Must read !!!! (09/02)
- The Truth about Sunscreen (06/26)
- 2016/07 (2)
- 2015/08 (1)
- 2013/09 (1)
- 2013/06 (2)
- 2013/05 (1)
- 2013/03 (2)
- 2012/11 (1)
- 2012/08 (1)
- 2011/10 (1)
- 2011/06 (2)
- 2011/05 (2)
- 2011/04 (1)
- 2011/02 (1)
- 2010/11 (1)
- 2010/10 (1)
- 2010/09 (4)
Friend request form